These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32495677)

  • 61. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J; Sims HM; Smith KH; Bramlage P
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry.
    Ono T; Ikemura N; Kimura T; Ueda I; Tanaka H; Tokuda H; Yajima N; Matsumura K; Suzuki M; Fukuda K; Kohsaka S; Takatsuki S
    J Cardiol; 2019 Jan; 73(1):14-21. PubMed ID: 30487057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
    Okumura K; Yamashita T; Suzuki S; Akao M;
    Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.
    Urbaniak AM; Strøm BO; Krontveit R; Svanqvist KH
    Drugs Aging; 2017 Aug; 34(8):635-645. PubMed ID: 28710707
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients.
    Lee KN; Choi JI; Boo KY; Kim DY; Kim YG; Oh SK; Baek YS; Lee DI; Roh SY; Shim J; Kim JS; Kim YH
    Sci Rep; 2020 Feb; 10(1):1801. PubMed ID: 32019993
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.
    Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):70-79. PubMed ID: 30423165
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
    Vimalesvaran K; Dockrill SJ; Gorog DA
    Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
    Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry.
    Tütüncü S; Olma M; Kunze C; Dietzel J; Schurig J; Fiessler C; Malsch C; Haas TE; Dimitrijeski B; Doehner W; Hagemann G; Hamilton F; Honermann M; Jungehulsing GJ; Kauert A; Koennecke HC; Mackert BM; Nabavi D; Nolte CH; Reis JM; Schmehl I; Sparenberg P; Stingele R; Völzke E; Waldschmidt C; Zeise-Wehry D; Heuschmann PU; Endress M; Haeusler KG
    J Neurol; 2022 Jan; 269(1):470-480. PubMed ID: 34718884
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
    BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 78. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
    BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.